Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
165 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-06-30
Study Completion Date
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese participants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
NCT01105975
Dyslipidemia
COMPLETED
PHASE2
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
NCT02260648
Hypercholesterolemia
TERMINATED
PHASE3
A Study of LY3478045 in Healthy Participants
NCT04270370
Healthy
COMPLETED
PHASE1
A Study in People With High Cholesterol
NCT00133380
Hypercholesterolemia
COMPLETED
PHASE2
LY2189265 and Atorvastatin Interaction Study
NCT01250834
Healthy Volunteers
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dyslipidemias
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
30 milligrams (mg) LY2484595
Administered orally once daily for 12 weeks
Group Type
EXPERIMENTAL
LY2484595
Intervention Type
DRUG
Administered orally
Placebo
Intervention Type
DRUG
Administered orally
100 mg LY2484595
Administered orally once daily for 12 weeks
Group Type
EXPERIMENTAL
LY2484595
Intervention Type
DRUG
Administered orally
Placebo
Intervention Type
DRUG
Administered orally
500 mg LY2484595
Administered orally once daily for 12 weeks
Group Type
EXPERIMENTAL
LY2484595
Intervention Type
DRUG
Administered orally
Placebo
Intervention Type
DRUG
Administered orally
Placebo
Administered orally once daily for 12 weeks
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Administered orally
10 mg Atorvastatin
Administered orally once daily for 12 weeks
Group Type
ACTIVE_COMPARATOR
Placebo
Intervention Type
DRUG
Administered orally
Atorvastatin
Intervention Type
DRUG
Administered orally
100 mg LY2484595 + 10 mg Atorvastatin
Administered orally once daily for 12 weeks
Group Type
EXPERIMENTAL
LY2484595
Intervention Type
DRUG
Administered orally
Placebo
Intervention Type
DRUG
Administered orally
Atorvastatin
Intervention Type
DRUG
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY2484595
Administered orally
Intervention Type
DRUG
Placebo
Administered orally
Intervention Type
DRUG
Atorvastatin
Administered orally
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Have Low HDL-C or High LDL-C criteria as follows:
Low HDL lipid criteria:
* HDL-C \<45 milligrams per deciliter (mg/dL) (men) and \<50 mg/dL (women), and
* LDL-C according to Japan Atherosclerosis Society (JAS) guidelines as follows:
* LDL-C \<190 mg/dL (0-1 risk factors)
* LDL-C \<160 mg/dL (2 risk factors)
* LDL-C \<130 mg/dL (3+ risk factors),and
* Fasting Triglycerides (TG) \<400 mg/dL
or
High LDL-C lipid criteria:
* HDL-C \<100 mg/dL, and
* LDL-C according to JAS guidelines as follows:
* LDL-C 100-190 mg/dL (0-1 risk factors)
* LDL-C 100-160 mg/dL (2 risk factors)
* LDL-C 100-130 mg/dL (3+ risk factors), and
* Fasting TG \<400 mg/dL
Note: Subjects with diabetes regarded as 3+ risk factors
* Male subjects: Agree to use a reliable method of birth control during the study (and for 2 weeks following the last dose of study drug)
* Female subjects: 1) Women not of childbearing potential due to surgical sterilization (at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history, or menopause. Menopausal women include women with either a) spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea \[for example, oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators (SERMs), or chemotherapy\] or b) spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level greater than 40 milli-international units per milliliter (mIU/mL). or, 2) Women of child bearing potential who test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test and agree to use a reliable method of birth control during the study and for 2 weeks following the last dose of study drug
* Have given informed consent to participate in the study
Low HDL lipid criteria:
* HDL-C \<45 milligrams per deciliter (mg/dL) (men) and \<50 mg/dL (women), and
* LDL-C according to Japan Atherosclerosis Society (JAS) guidelines as follows:
* LDL-C \<190 mg/dL (0-1 risk factors)
* LDL-C \<160 mg/dL (2 risk factors)
* LDL-C \<130 mg/dL (3+ risk factors),and
* Fasting Triglycerides (TG) \<400 mg/dL
or
High LDL-C lipid criteria:
* HDL-C \<100 mg/dL, and
* LDL-C according to JAS guidelines as follows:
* LDL-C 100-190 mg/dL (0-1 risk factors)
* LDL-C 100-160 mg/dL (2 risk factors)
* LDL-C 100-130 mg/dL (3+ risk factors), and
* Fasting TG \<400 mg/dL
Note: Subjects with diabetes regarded as 3+ risk factors
* Male subjects: Agree to use a reliable method of birth control during the study (and for 2 weeks following the last dose of study drug)
* Female subjects: 1) Women not of childbearing potential due to surgical sterilization (at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history, or menopause. Menopausal women include women with either a) spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea \[for example, oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators (SERMs), or chemotherapy\] or b) spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level greater than 40 milli-international units per milliliter (mIU/mL). or, 2) Women of child bearing potential who test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test and agree to use a reliable method of birth control during the study and for 2 weeks following the last dose of study drug
* Have given informed consent to participate in the study
Exclusion Criteria
* At screening, are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* Have participated within 90 days prior to screening in any clinical trials of cholesteryl ester transfer protein (CETP) inhibitors (e.g., anacetrapib or dalcetrapib)
* Have completed or withdrawn from this study or have completed or withdrawn from any other study investigating LY2484595
* Are unable, unreliable, and/or unwilling to provide informed consent, make themselves available for the duration of the study, or will not abide by the procedures and study restrictions
* Have recent history of any clinically significant rash, history of any clinically severe drug-related rash, history of a chronic skin disorder (such as psoriasis, eczema or urticaria), history of significant skin hypersensitivities to household or cosmetic products, or allergens per the investigator, or presence of widespread tattoos or other skin condition that limits the assessment for rashes. Subjects who develop any rash during the Diet Lead-in/Washout Phase cannot be randomized
* Have or have had any clinical manifestation of coronary heart disease (CHD), such as stable or unstable angina, acute coronary syndrome, myocardial infarction, or a coronary revascularization procedure including stent placement, symptomatic carotid artery disease or symptomatic peripheral arterial disease. Subjects with a diagnosis of abdominal aortic aneurysm are excluded from this study
* Have systolic blood pressure (SBP) \>140 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>90 mm Hg as determined by the mean of 3 standardized measurements in the sitting position at randomization
* Have or have had documented hyperaldosteronism
* Have symptoms consistent with moderate or severe heart failure or are receiving treatment for symptomatic congestive heart failure (CHF) or known left ventricular ejection fraction (LVEF) \<35%. The absence of LVEF measurement does not prohibit entry into this study
* Have one of the following abnormalities: QTc prolongation \[Bazett's corrected QT interval (QTcB)\] of \>450 msec in male subjects or \>470 msec in female subjects, or abnormally wide QRS complexes (resulting from bundle branch blocks, intraventricular conduction delays, or pacemakers) or atrial fibrillation on screening electrocardiogram (ECG), previous history of QTc prolongation with another medication that required discontinuation, congenital long QT syndrome, previous history of ventricular tachycardia or unexplained syncope
* Have family history of long QT syndrome or sudden death likely secondary to ventricular arrhythmia
* Have active hepatobiliary disease, serologic evidence of past or active hepatitis B or C, or past or active gallbladder disease. Subjects who have been diagnosed with Gilbert syndrome or had a cholecystectomy greater than 90 days prior to screening can be included
* Have aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), alkaline phosphatase (ALP), or total bilirubin \>1.5 times the upper limit of normal (ULN)
* Have a history or presence of a chronic muscular or neuromuscular disease including prior rhabdomyolysis or drug-induced myopathy or an unexplained/documented elevation in creatine kinase (CK) ≥3 times the ULN
* Have a history of discontinuation from statin, change of statin, or a dose reduction of statin due to history of hypersensitivity, intolerance or adverse effect. Have a history of increased hepatic enzymes associated with use of an hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin)
* Have a history of hypersensitivity or intolerance to drug preparations containing cholesteryl ester transfer protein (CETP) inhibitors, including but not limited to torcetrapib, anacetrapib, or dalcetrapib
* Have a hemoglobin A1c ≥8.0%; or use, plan to use, or are likely to require insulin during the course of the study. Diabetic subjects on an antidiabetic agent with lipid modifying effects must be on a stable dose for at least 30 days prior to screening
* Have a serum creatinine ≥2 mg/dL, or nephrotic syndrome, end stage renal disease and use renal replacement therapy such as hemodialysis or peritoneal dialysis
* Have hemoglobin \<10 grams per deciliter (g/dL) in women and \<11 g/dL in men
* Have current uncontrolled active inflammatory condition or infection which in the opinion of the investigator would influence a subject's ability to complete the study
* Have thyroid-stimulating hormone (TSH) levels outside normal reference range. Subjects who are clinically euthyroid, on stable thyroid replacement therapy for 60 days prior to screening, and are anticipated to remain on this dose throughout the trial period are acceptable exceptions to this criterion
* Are women who are lactating
* Have planned or are likely to require major surgery requiring anesthesia or hospitalization during the course of the study
* Have chronic alcohol or drug abuse or dependency
* Are currently under suspicion of having cancer or have had a history of cancer in the past 2 years, with the exception of excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin
* Have history of human immunodeficiency virus (HIV) infection
* Have any other condition or abnormal laboratory value, which in the opinion of the investigator precludes the subject from providing informed consent
* Plan to use, are likely to require, or unwilling or unable to stop with adequate washout any prescription or over-the-counter (OTC) medication or health foods with the intent to treat serum lipids (LDL-C, HDL-C, triglycerides) including but not limited to these classes of drugs: statin, ezetimibe, bile acid sequestrant, eicosapentaenoic acid (EPA). Subjects taking probucol, fibrate or nicotinic agents within 8 weeks before screening are excluded from the study
* Are currently using, plan to use, or are likely to require during the course of the study systemic corticosteroids; or anabolic agents other than stable doses of estrogen, estrogen/progestin, or testosterone replacement therapy
* Are currently using, plan to use, or are likely to require during the course of the study, more than the occasional use (i.e., once every other week) of stimulant laxatives (e.g., bisacodyl), osmotic laxatives (e.g., milk of magnesia), or castor oil
* Use of any immunosuppressive therapy within 60 days prior to screening or are likely to require immunosuppressive therapy during the course of the study
* Have received treatment within 30 days prior to the time of study entry with any drug or drugs that have not received regulatory approval for any indication
* Have plans to adopt diets with aggressive carbohydrate restrictions for weight loss. Currently use, have used within 60 days prior to screening, or plan to use during the trial period prescriptions or OTC formulations intended for weight loss
* Are currently using, have used within 60 days prior to screening, plan to use, or are likely to require during the course of the study, drugs or foods that are inducers (including rifampin and carbamazepine) or moderate or strong inhibitors of cytochrome P450 3A (including, ketoconazole, erythromycin and grapefruit juice); or strong inhibitors of the organic anion transporter polypeptide 1B1 (OATP1B1) transporter (including cyclosporine and rifampin). The drugs used in topical preparations are acceptable
* Have participated within 90 days prior to screening in any clinical trials of cholesteryl ester transfer protein (CETP) inhibitors (e.g., anacetrapib or dalcetrapib)
* Have completed or withdrawn from this study or have completed or withdrawn from any other study investigating LY2484595
* Are unable, unreliable, and/or unwilling to provide informed consent, make themselves available for the duration of the study, or will not abide by the procedures and study restrictions
* Have recent history of any clinically significant rash, history of any clinically severe drug-related rash, history of a chronic skin disorder (such as psoriasis, eczema or urticaria), history of significant skin hypersensitivities to household or cosmetic products, or allergens per the investigator, or presence of widespread tattoos or other skin condition that limits the assessment for rashes. Subjects who develop any rash during the Diet Lead-in/Washout Phase cannot be randomized
* Have or have had any clinical manifestation of coronary heart disease (CHD), such as stable or unstable angina, acute coronary syndrome, myocardial infarction, or a coronary revascularization procedure including stent placement, symptomatic carotid artery disease or symptomatic peripheral arterial disease. Subjects with a diagnosis of abdominal aortic aneurysm are excluded from this study
* Have systolic blood pressure (SBP) \>140 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>90 mm Hg as determined by the mean of 3 standardized measurements in the sitting position at randomization
* Have or have had documented hyperaldosteronism
* Have symptoms consistent with moderate or severe heart failure or are receiving treatment for symptomatic congestive heart failure (CHF) or known left ventricular ejection fraction (LVEF) \<35%. The absence of LVEF measurement does not prohibit entry into this study
* Have one of the following abnormalities: QTc prolongation \[Bazett's corrected QT interval (QTcB)\] of \>450 msec in male subjects or \>470 msec in female subjects, or abnormally wide QRS complexes (resulting from bundle branch blocks, intraventricular conduction delays, or pacemakers) or atrial fibrillation on screening electrocardiogram (ECG), previous history of QTc prolongation with another medication that required discontinuation, congenital long QT syndrome, previous history of ventricular tachycardia or unexplained syncope
* Have family history of long QT syndrome or sudden death likely secondary to ventricular arrhythmia
* Have active hepatobiliary disease, serologic evidence of past or active hepatitis B or C, or past or active gallbladder disease. Subjects who have been diagnosed with Gilbert syndrome or had a cholecystectomy greater than 90 days prior to screening can be included
* Have aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), alkaline phosphatase (ALP), or total bilirubin \>1.5 times the upper limit of normal (ULN)
* Have a history or presence of a chronic muscular or neuromuscular disease including prior rhabdomyolysis or drug-induced myopathy or an unexplained/documented elevation in creatine kinase (CK) ≥3 times the ULN
* Have a history of discontinuation from statin, change of statin, or a dose reduction of statin due to history of hypersensitivity, intolerance or adverse effect. Have a history of increased hepatic enzymes associated with use of an hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin)
* Have a history of hypersensitivity or intolerance to drug preparations containing cholesteryl ester transfer protein (CETP) inhibitors, including but not limited to torcetrapib, anacetrapib, or dalcetrapib
* Have a hemoglobin A1c ≥8.0%; or use, plan to use, or are likely to require insulin during the course of the study. Diabetic subjects on an antidiabetic agent with lipid modifying effects must be on a stable dose for at least 30 days prior to screening
* Have a serum creatinine ≥2 mg/dL, or nephrotic syndrome, end stage renal disease and use renal replacement therapy such as hemodialysis or peritoneal dialysis
* Have hemoglobin \<10 grams per deciliter (g/dL) in women and \<11 g/dL in men
* Have current uncontrolled active inflammatory condition or infection which in the opinion of the investigator would influence a subject's ability to complete the study
* Have thyroid-stimulating hormone (TSH) levels outside normal reference range. Subjects who are clinically euthyroid, on stable thyroid replacement therapy for 60 days prior to screening, and are anticipated to remain on this dose throughout the trial period are acceptable exceptions to this criterion
* Are women who are lactating
* Have planned or are likely to require major surgery requiring anesthesia or hospitalization during the course of the study
* Have chronic alcohol or drug abuse or dependency
* Are currently under suspicion of having cancer or have had a history of cancer in the past 2 years, with the exception of excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin
* Have history of human immunodeficiency virus (HIV) infection
* Have any other condition or abnormal laboratory value, which in the opinion of the investigator precludes the subject from providing informed consent
* Plan to use, are likely to require, or unwilling or unable to stop with adequate washout any prescription or over-the-counter (OTC) medication or health foods with the intent to treat serum lipids (LDL-C, HDL-C, triglycerides) including but not limited to these classes of drugs: statin, ezetimibe, bile acid sequestrant, eicosapentaenoic acid (EPA). Subjects taking probucol, fibrate or nicotinic agents within 8 weeks before screening are excluded from the study
* Are currently using, plan to use, or are likely to require during the course of the study systemic corticosteroids; or anabolic agents other than stable doses of estrogen, estrogen/progestin, or testosterone replacement therapy
* Are currently using, plan to use, or are likely to require during the course of the study, more than the occasional use (i.e., once every other week) of stimulant laxatives (e.g., bisacodyl), osmotic laxatives (e.g., milk of magnesia), or castor oil
* Use of any immunosuppressive therapy within 60 days prior to screening or are likely to require immunosuppressive therapy during the course of the study
* Have received treatment within 30 days prior to the time of study entry with any drug or drugs that have not received regulatory approval for any indication
* Have plans to adopt diets with aggressive carbohydrate restrictions for weight loss. Currently use, have used within 60 days prior to screening, or plan to use during the trial period prescriptions or OTC formulations intended for weight loss
* Are currently using, have used within 60 days prior to screening, plan to use, or are likely to require during the course of the study, drugs or foods that are inducers (including rifampin and carbamazepine) or moderate or strong inhibitors of cytochrome P450 3A (including, ketoconazole, erythromycin and grapefruit juice); or strong inhibitors of the organic anion transporter polypeptide 1B1 (OATP1B1) transporter (including cyclosporine and rifampin). The drugs used in topical preparations are acceptable
Minimum Eligible Age
20 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hyōgo, , Japan
Site Status
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kanagawa, , Japan
Site Status
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kyoto, , Japan
Site Status
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Osaka, , Japan
Site Status
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tokyo, , Japan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Japan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I1V-JE-EIAE
Identifier Type: OTHER
Identifier Source: secondary_id
13049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
NCT00689442
COMPLETED
PHASE2
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
NCT02714569
COMPLETED
PHASE1
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
NCT02055976
COMPLETED
PHASE2
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
NCT00977288
COMPLETED
PHASE2
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
NCT01859455
COMPLETED
PHASE1
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
NCT02260635
TERMINATED
PHASE3
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
NCT01760460
COMPLETED
PHASE3
A Study of LY3015014 in Healthy Participants With High Cholesterol
NCT01671085
COMPLETED
PHASE1
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
NCT01285544
COMPLETED
PHASE4
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
NCT03438955
UNKNOWN
PHASE1
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
NCT00504829
COMPLETED
PHASE2
A Study of LY3015014 in Participants With High Cholesterol
NCT01890967
COMPLETED
PHASE2
A Study of LY3502970 in Healthy Participants
NCT03929744
COMPLETED
PHASE1
Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
NCT00640549
TERMINATED
PHASE4
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550
NCT01059864
COMPLETED
PHASE2
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
NCT01544309
COMPLETED
NA
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
NCT02460159
COMPLETED
PHASE3
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
NCT01812707
COMPLETED
PHASE2
Evaluation of Atorvastatin Treatment on Carotid Plaque.
NCT00343655
TERMINATED
PHASE3
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
NCT05365438
RECRUITING
PHASE4
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
NCT00300469
COMPLETED
PHASE3
Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
NCT01974297
UNKNOWN
NA
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
NCT02584504
COMPLETED
PHASE3
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
NCT00664859
COMPLETED
PHASE2/PHASE3